{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:13:20Z","timestamp":1790363600599,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003-0014"],"award-info":[{"award-number":["HDTRA1-12-D-0003-0014"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jconrel.2020.05.048","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:04:41Z","timestamp":1591329881000},"page":"644-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Glucosamine-NISV delivers antibody across the blood-brain barrier: Optimization for treatment of encephalitic viruses"],"prefix":"10.1016","volume":"324","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3798-2074","authenticated-orcid":false,"given":"Stuart","family":"Woods","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn M.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Georgian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Diane","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Modino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Joan","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo V.","family":"D'Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.05.048_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2011.01.010","article-title":"A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus","volume":"90","author":"Goodchild","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.virol.2012.01.038","article-title":"A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge","volume":"426","author":"O'Brien","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.18433\/J3230M","article-title":"Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting","volume":"15","author":"Bragagni","year":"2012","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0025","first-page":"1","article-title":"Nano-niosomes in drug, vaccine and gene delivery: a rapid overview","volume":"1","author":"Pardakhty","year":"2013","journal-title":"Nanomed. J."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jconrel.2019.02.002","article-title":"Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments","volume":"298","author":"D\u2019Elia","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717544.2013.838077","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations","volume":"21","author":"Abdelkader","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0040","first-page":"6847971","article-title":"Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier","volume":"2018","author":"Gharbavi","year":"2018","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0045","series-title":"New Concepts of a Blood\u2014Brain Barrier","first-page":"81","article-title":"Molecular regulation of blood-brain barrier GLUT1 glucose transporter","author":"Pardridge","year":"1995"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0055","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","article-title":"Sugar for the brain: the role of glucose in physiological and pathological brain function","volume":"36","author":"Mergenthaler","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpharm.2004.07.020","article-title":"Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain","volume":"285","author":"Dufes","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2014.01.006","article-title":"Development and characterization of functionalized niosomes for brain targeting of dynorphin-B","volume":"87","author":"Bragagni","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2008.09.005","article-title":"Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin","volume":"133","author":"Hong","year":"2009","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4155\/tde.13.21","article-title":"Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells","volume":"4","author":"Duf\u00e8s","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152604","article-title":"Characterization of genetic variability of Venezuelan equine encephalitis viruses","volume":"11","author":"Gardner","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0085","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1086\/513978","article-title":"Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995","volume":"175","author":"Rivas","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0090","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/fvl.11.50","article-title":"Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella","volume":"6","author":"Aguilar","year":"2011","journal-title":"Futur. Virol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0095","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1371\/journal.pntd.0000472","article-title":"Venezuelan equine encephalitis in Panama: fatal endemic disease and genetic diversity of etiologic viral strains","volume":"3","author":"Quiroz","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2017.04.008","article-title":"Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection","volume":"308","author":"Cain","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijpharm.2018.11.060","article-title":"Rapid and scale-independent microfluidic manufacture of liposomes entrapping protein incorporating in-line purification and at-line size monitoring","volume":"556","author":"Forbes","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.015","article-title":"Nano-niosomes as nanoscale drug delivery systems: an illustrated review","volume":"185","author":"Moghassemi","year":"2014","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0115","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1021\/nn501069c","article-title":"A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer","volume":"8","author":"Li","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/30.2.7061816","article-title":"Cytotoxicity, mutagenicity and DNA damage by Hoechst 33342","volume":"30","author":"Durand","year":"1982","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0125","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1002\/jps.24398","article-title":"Quantitative determination of luminal and abluminal membrane distributions of transporters in porcine brain capillaries by plasma membrane fractionation and quantitative targeted proteomics","volume":"104","author":"Kubo","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrm3266","article-title":"Dynamin, a membrane-remodelling GTPase","volume":"13","author":"Ferguson","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0135","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1073\/pnas.78.11.6936","article-title":"Carbohydrate-specified endocytosis: localization of ligand in the lysosomal compartment","volume":"78","author":"Haimes","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0145","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-007-9387-0","article-title":"Brain drug development and brain drug targeting","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1602\/neurorx.2.1.108","article-title":"Drug transport to brain with targeted nanoparticles","volume":"2","author":"Olivier","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0155","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.1991.9.9.1580","article-title":"Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function","volume":"9","author":"Neuwelt","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0160","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.7150\/thno.21225","article-title":"Focused ultrasound immunotherapy for central nervous system pathologies: challenges and opportunities","volume":"7","author":"Curley","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0165","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","article-title":"Blood-brain barrier transport of therapeutics via receptor-mediation","volume":"24","author":"Jones","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/B:PHAM.0000012156.65125.01","article-title":"Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles","volume":"21","author":"Dufes","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032568","article-title":"Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model","volume":"7","author":"Wagner","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.048_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0190","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016758","article-title":"Clathrin-independent pathways of endocytosis","volume":"6","author":"Mayor","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.addr.2012.09.041","article-title":"Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances","volume":"65","author":"Xu","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0200","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tcb.2017.11.004","article-title":"Mechanisms of carrier formation during clathrin-independent endocytosis","volume":"28","author":"Ferreira","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","article-title":"The SLC2 (GLUT) family of membrane transporters","volume":"34","author":"Mueckler","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10847-006-9250-7","article-title":"A versatile liposome\/cyclodextrin supramolecular carrierfor drug delivery through the blood-brain barrier","volume":"57","author":"Machut-Binkowski","year":"2007","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32033-w","article-title":"Lipid-coated Mesoporous silica nanoparticles for the delivery of the ML336 antiviral to inhibit encephalitic alphavirus infection","volume":"8","author":"LaBauve","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0220","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes of laboratory animals","volume":"150","author":"Guyton","year":"1947","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jconrel.2020.05.048_bb0225","first-page":"e56277","article-title":"Improved method for the establishment of an in vitro blood-brain barrier model based on porcine brain endothelial cells","volume":"127","author":"Nielsen","year":"2017","journal-title":"J. Vis. Exp."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:54:31Z","timestamp":1759161271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920303254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"alternative-id":["S0168365920303254"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.048","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucosamine-NISV delivers antibody across the blood-brain barrier: Optimization for treatment of encephalitic viruses","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}